Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Acquired APT-1011, a Phase 3-evaluated EoE candidate, for $20 million in stock with no upfront cash payment.
ABEONA THERAPEUTICS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Acquired APT-1011, a Phase 3-evaluated EoE candidate, for $20 million in stock with no upfront cash payment
- Issued Ellodi 4,494,383 shares, creating immediate dilution and potential future selling pressure after staggered lock-up releases
- Future consideration includes $30 million upon FDA approval, up to $30 million in sales milestones, and low-to-mid-teens royalties
- Private placement targets approximately $30 million through 6,400,000 shares and pre-funded warrants for 1,600,043 shares
- Financing supports pipeline development and ZEVASKYN commercialization, but adds substantial equity dilution and resale-registration overhang
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Item 2.01 contains no separate transaction details
- Acquisition or disposition terms are incorporated from Item 1.01
- Investor impact depends on the referenced material agreement and its financial obligations
Item 3.02 · Unregistered Sales of Equity Securities
- Item 3.02 links an unregistered equity issuance to the financing or transaction described in Item 1.01
- Investor impact depends on Item 1.01 terms, including securities issued, pricing, dilution and investor rights
Item 7.01 · Regulation FD Disclosure
- November 9, 2026 press release announced the Transaction, with terms in Exhibit 99.1
- Investor presentation, “APT-1011 Clinical Development History,” provides supporting clinical-development context in Exhibit 99.2
- Transaction announcement and APT-1011 history may affect investor assessment of pipeline value and development prospects
Item EX-99.1 · Exhibit EX-99.1
- Acquired ABO-801, a Phase 3-ready oral EoE candidate, for $20 million in Abeona equity with no upfront cash
- Prior Phase 3 studies missed co-primary symptom endpoints, though endoscopic measures improved significantly
- Planned Phase 3 study targeted for Q2 2027, with topline results anticipated by end-2028
- $30 million private placement: 6,400,000 shares at $3.75 plus warrants for 1,600,043 shares, creating substantial equity dilution
- Seller eligible for $30 million FDA approval payment, up to $30 million sales milestones and tiered royalties at low-to-mid teen percentages
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ABEONA THERAPEUTICS INC. 8-K filings
Get the next ABEO 8-K as it lands
Follow ABEO for push alerts, or ask the research agent what this filing means.